Randomised Controlled Trials to Assess Approved SARS-CoV-2 Vaccines in Immunocompromised Patients: A Master Protocol for the Set-up of a Swiss Cohorts Based Trial Platform
Phase: PHASE3
Conditions: Immunocompromised Patients
Sponsor: University Hospital, Basel, Switzerland

Clinical Study first sub-protocol 
 
Randomised controlled trials to assess approved SARS-CoV-2 vaccines in 
immunocompromised patients: First sub-protocol for a pilot trial comparing the 
mRNA vaccines Comirnaty® and Covid-19 mRNA Vaccine Moderna® 
 
 
This is the first sub-protocol linked to the mast protocol entitled “Randomised controlled trials to 
assess approved SARS-CoV-2 vaccines in immunocompromised patients: A master protocol for 
the set-up of a Swiss Cohorts Based Trial Platform” (submitted to ethical committee: 15.12.2020, 
provisional approval: 01.04.2021; finally approved: 19.04.2021; ID number 2021-000593). 
 
Short title: Immunocompromised Swiss Cohorts Based Trial Platform 
Acronym: COVERALL (COrona VaccinE tRiAL pLatform) 
 
 
 
Study Type: 
Clinical trial with Investigational Medicinal Product (IMP) 
Study Categorisation: 
Category A 
Study Registration: 
Clinicaltrials.gov: NCT04805125Planned: kofam 
Study Identifier: 
COVERALL 
Sponsor, Sponsor-Investigator or 
Principal Investigator: 
University Hospital Basel 
Prof. Heiner C. Bucher MD MPH 
Basel Institute for Clinical Epidemiology & Biostatistics 
University Hospital Basel 
Spitalstrasse 12 
4056 Basel 
Switzerland 
Phone: +41 (0)61 328 61 01 
Email: heiner.bucher@usb.ch 
Investigational Product: 
mRNA  vaccines  Comirnaty®   and  Covid-19  mRNA  Vaccine 
Moderna® 
Protocol Version and Date: 
Version 1.1; 07. 04. 2021 
 
 
 
 
 
CONFIDENTIAL 
The information contained in this document is explicitly not confidential. We will make all study protocols (including 
master protocol, sub-protocols, as well as amendments) publicly available on Open Science Framework 
(https://osf.io/) 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 2 of 44 
 
Signature Page(s) 
 
 
 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 3 of 44 
 
Authors of the study protocol: 
 
Benjamin Speich, PhD 
Prof. Heiner C. Bucher MD MPH 
PD Michael Koller, PhD 
Prof. Nicolas Müller MD 
Prof. Huldyrch Günthard MD PhD 
Prof. Andri Rauch MD PhD 
Prof. Matthias Briel MD, PhD, MSc 
PD Lars G. Hemkens, MD, MPH 
 
Trial statistician: 
Frédérique Chammartin, PhD 
 
Data Management: 
Katharina Kusejko, PhD 
Daniel Smith 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 4 of 44 
 
 
 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 5 of 44 
 
 
 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 6 of 44 
 
 
 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 7 of 44 
 
 
 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 8 of 44 
 
 
 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 9 of 44 
 
 
 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 10 of 44 
 
 
 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 11 of 44 
 
 
 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 12 of 44 
 
 
 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 13 of 44 
 
In the master protocol (submitted to ethical committee on the 15. December 2020; EC ID 2021- 
000593) we described the platform and the outline for our pilot trial which will randomise patients from 
the Swiss Transplant Cohort Study (STCS) and the Swiss HIV Cohort Study (SHCS) to the two SARS- 
CoV-2 vaccines that are first approved in Switzerland. In the meantime the first two SARS-CoV-2 
vaccines reached market authorisation by Swissmedic. Therefore, we present here in the first sub- 
protocol of a head to head comparison of the vaccines by Pfizer/Biontech and Moderna for use in 
immune- compromised patient and provide the following iinformation that could not be specified in the 
master protocol, because interventions were not yet approved: 
 
• 
Updated Study schedule 
• 
Current available evidence for the two selected study interventions comparison 
• 
Updated inclusion and exclusion criteria 
• 
Specific description of the interventions (i.e. application, dosage, storage conditions, 
concomitant treatment). 
 
 
 
 
Table of Contents 
ABBREVIATIONS ................................................................................................................................. 16 
STUDY SYNOPSIS ............................................................................................................................... 18 
STUDY SCHEDULE .............................................................................................................................. 19 
1. 
STUDY ADMINISTRATIVE STRUCTURE .................................................................................... 20 
1.1 
Sponsor-Investigator ................................................................................................................... 20 
1.2 
Local Principal Investigator(s) ..................................................................................................... 20 
1.3 
Statistician ("Biostatistician") ....................................................................................................... 21 
1.4 
Laboratory ................................................................................................................................... 21 
1.5 
Co-investigators ........................................................................................................................... 21 
1.6 
Monitoring institution ................................................................................................................... 22 
1.7 
Data Safety Monitoring Committee ............................................................................................. 22 
1.8 
Any other relevant Committee, Person, Organisation, Institution ............................................... 22 
1.9 
Authors contributions ................................................................................................................... 22 
2. 
ETHICAL AND REGULATORY ASPECTS ................................................................................... 23 
2.1 
Study registration ........................................................................................................................ 23 
2.2 
Categorisation of study ............................................................................................................... 23 
2.3 
Competent Ethics Committee (CEC) .......................................................................................... 23 
2.4 
Competent Authorities (CA) ........................................................................................................ 23 
2.5 
Ethical Conduct of the Study ....................................................................................................... 23 
2.6 
Declaration of interest ................................................................................................................. 23 
2.7 
Patient Information and Informed Consent .................................................................................. 23 
2.8 
Participant privacy and confidentiality ......................................................................................... 23 
2.9 
Early termination of the study ...................................................................................................... 23 
2.10 Protocol amendments ................................................................................................................. 23 
3. 
BACKGROUND AND RATIONALE .............................................................................................. 23 
3.1 
Background and Rationale .......................................................................................................... 23 
3.2 
Investigational Product (treatment, device) and Indication .......................................................... 24 
3.3 
Preclinical Evidence .................................................................................................................... 24 
3.4 
Clinical Evidence to Date ............................................................................................................ 26 
3.5 
Dose Rationale / Medical Device: Rationale for the intended purpose in study (pre-market 
MD) 29 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 14 of 44 
 
3.6 
Explanation for choice of comparator (or placebo) ..................................................................... 29 
3.7 
Risks / Benefits ............................................................................................................................ 29 
3.8 
Justification of choice of study population ................................................................................... 30 
4. 
STUDY OBJECTIVES ................................................................................................................... 31 
4.1 
Overall Objective ......................................................................................................................... 31 
4.2 
Objectives related to platform trial set-up and feasibility of cohort based patient recruit, trial 
inclusion and data collection .................................................................................................................. 31 
4.3 
Objectives  related  to  a  platform  based  nested  pilot  trial  to  investigate  the  comparative 
effectiveness of vaccines against Sars-CoV-2 ...................................................................................... 31 
4.4 
Safety Objectives ........................................................................................................................ 31 
5. 
STUDY OUTCOMES ..................................................................................................................... 31 
5.1 
Immunological Outcomes ............................................................................................................ 31 
5.2 
Clinical Outcomes ....................................................................................................................... 32 
5.3 
Other Outcomes of Interest ......................................................................................................... 32 
5.4 
Safety Outcomes ......................................................................................................................... 32 
6. 
STUDY DESIGN ............................................................................................................................ 33 
6.1 
General study design and justification of design ......................................................................... 33 
6.2 
Methods of minimising bias ......................................................................................................... 33 
6.2.1 Randomisation .................................................................................................................... 33 
6.2.2 Blinding procedures............................................................................................................. 33 
6.2.3 Other methods of minimising bias ....................................................................................... 33 
6.3 
Unblinding Procedures (Code break) .......................................................................................... 33 
7. 
STUDY POPULATION ................................................................................................................... 33 
7.1 
Eligibility criteria ........................................................................................................................... 34 
7.2 
Recruitment and screening ......................................................................................................... 34 
7.3 
Assignment to study groups ........................................................................................................ 34 
7.4 
Criteria for withdrawal / discontinuation of participants ............................................................... 34 
8. 
STUDY INTERVENTION ............................................................................................................... 34 
8.1 
Identity of Investigational Products (treatment / medical device) ................................................ 34 
8.1.1 Experimental Intervention (treatment / medical device) ...................................................... 35 
8.1.2 Control Intervention (standard/routine/comparator treatment / medical device) ................. 35 
8.1.3 Packaging, Labelling and Supply (re-supply) ...................................................................... 35 
8.1.4 Storage Conditions .............................................................................................................. 35 
8.2 
Administration of experimental and control interventions ........................................................... 36 
8.2.1 Experimental Intervention ................................................................................................... 36 
8.2.2 Control Intervention ............................................................................................................. 36 
8.3 
Dose / Device modifications ........................................................................................................ 36 
8.4 
Compliance with study intervention ............................................................................................. 36 
8.5 
Data Collection and Follow-up for withdrawn participants .......................................................... 36 
8.6 
Trial specific preventive measures .............................................................................................. 37 
8.7 
Concomitant Interventions (treatments) ...................................................................................... 37 
8.8 
Study Drug / Medical Device Accountability ................................................................................ 37 
8.9 
Return or Destruction of Study Drug / Medical Device ................................................................ 37 
9. 
STUDY ASSESSMENTS ............................................................................................................... 37 
9.1 
Study flow chart(s) / table of study procedures and assessments .............................................. 37 
9.2 
Assessments of outcomes .......................................................................................................... 38 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 15 of 44 
 
9.2.1 Assessment of feasibility outcomes .................................................................................... 38 
9.2.2 Assessment of immunological endpoints ............................................................................ 38 
9.2.3 Assessment of clinical endpoints ........................................................................................ 39 
9.2.4 Assessment of safety outcomes ......................................................................................... 39 
9.2.5 Assessments in participants who prematurely stop the study ............................................ 40 
9.2.6 Assessments in participants who prematurely stop the study ............................................ 40 
9.3 
Procedures at each visit .............................................................................................................. 40 
9.3.1 Eligibility (and eventual enrolment, randomisation) ............................................................ 40 
9.3.2 Enrolment and randomisation ............................................................................................. 40 
9.3.3 Follow-up 1 week 12 ........................................................................................................... 40 
9.3.4 Follow-up 2 week 48 ........................................................................................................... 40 
10. SAFETY ......................................................................................................................................... 40 
10.1 Drug studies ................................................................................................................................ 40 
10.1.1 Reporting of serious adverse events (SAE) and other safety related events...................... 40 
10.1.2 Follow up of (Serious) Adverse Events ............................................................................... 41 
11. STATISTICAL METHODS ............................................................................................................. 41 
11.1 Hypothesis ................................................................................................................................... 41 
11.2 Determination of Sample Size ..................................................................................................... 41 
11.3 Statistical criteria of termination of trial ....................................................................................... 41 
11.4 Planned Analyses ........................................................................................................................ 41 
11.4.1 Datasets to be analysed, analysis populations ................................................................... 41 
11.4.2 Feasibility analysis .............................................................................................................. 41 
11.4.3 Analyses of immunological and clinical outcomes .............................................................. 41 
11.4.4 Interim analyses .................................................................................................................. 42 
11.4.5 Safety analysis .................................................................................................................... 42 
11.4.6 Deviation(s) from the original statistical plan ....................................................................... 42 
11.5 Handling of missing data and drop-outs ...................................................................................... 42 
12. QUALITY ASSURANCE AND CONTROL .................................................................................... 42 
12.1 Data handling and record keeping / archiving ............................................................................. 42 
12.2 Data management ....................................................................................................................... 42 
12.3 Monitoring .................................................................................................................................... 42 
12.4 Audits and Inspections ................................................................................................................ 42 
12.5 Confidentiality, Data Protection ................................................................................................... 42 
12.6 Storage of biological material and related health data ................................................................ 42 
13. PUBLICATION AND DISSEMINATION POLICY .......................................................................... 43 
14. FUNDING AND SUPPORT ............................................................................................................ 43 
15. INSURANCE .................................................................................................................................. 43 
16. REFERENCES ............................................................................................................................... 43 
17. APPENDICES ................................................................................................................................ 44 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 16 of 44 
 
ABBREVIATIONS 
 
 
AE 
Adverse Event 
BAG 
Bundesamt für Gesundheitswesen 
BASEC 
Business Administration System for Ethical Committees, 
(https://submissions.swissethics.ch/en/) 
BOD 
Burden of disease 
CA 
Competent Authority (e.g. Swissmedic) 
CEC 
Competent Ethics Committee 
COVID 
Corona virus diseases 
CRF 
Case Report Form 
ClinO 
Ordinance on Clinical Trials in Human Research (in German: KlinV, in French: 
OClin, in Italian: OSRUm) 
CONSORT 
Consolidated Standards of Reporting Trials 
eCRF 
Electronic Case Report Form 
CTCAE 
Common terminology criteria for adverse events 
DSUR 
Development safety update report 
FDA 
Food and drug administration 
GCP 
Good Clinical Practice 
GMT 
Geometric mean titers 
IB 
Investigator’s Brochure 
Ho 
Null hypothesis 
H1 
Alternative hypothesis 
HIV 
Human Immunodeficiency Virus 
HRA 
Federal Act on Research involving Human Beings (in German: HFG, in French: 
LRH, in Italian: LRUm) 
IMP 
Investigational Medicinal Product 
IIT 
Investigator-initiated Trial 
ISO 
International Organisation for Standardisation 
ITT 
Intention to treat 
MD 
Medical Device 
MedDO 
Medical Device Ordinance (in German: MepV, in French: ODim) 
PI 
Principal Investigator 
RBD 
Receptor binding domain 
RECORD 
REporting of studies Conducted using Observational Routinely-collected Data 
SARS-CoV-2 
Severe acute respiratory syndrome coronavirus 2 
SDV 
Source Data Verification 
SHCS 
Swiss HIV Cohort Study 
SOP 
Standard Operating Procedure 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 17 of 44 
 
 
SPC 
Summary of product characteristics 
SPIRIT 
Standard Protocol Items: Recommendations for Interventional Trials 
STCS 
Swiss Transplant Cohort Study 
SUSAR 
Suspected Unexpected Serious Adverse Reaction 
TMF 
Trial Master File 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 18 of 44 
 
STUDY SYNOPSIS 
 
Randomised controlled trials to assess approved SARS-CoV-2 vaccines in 
immunocompromised patients: First sub-protocol for a pilot trial comparing the 
mRNA vaccines Comirnaty® and Covid-19 mRNA Vaccine Moderna® 
 
Brief Title: Immunocompromised Swiss Cohorts Based Trial Platform, 
Acronym: COVERALL (COrona VaccinE tRiAL pLatform) 
 
Rationale: A new highly contagious corona virus SARS-CoV-2 has emerged in late 2019 in Wuhan, 
China, and caused in a two-month period a pandemic with the highest disease burden in elderly and 
people with pre-existing medical conditions. After nearly one year into the epidemic over 0.5 milllion 
infections, over 21’000 hospitalisations, and over 82000 deaths due to Sars-CoV-2 have been recorded 
in Switzerland (January 21, 2021). 
Since January 12, 2021 two mRNA vaccines against Sars-CoV-2 by Pfizer / BioNTech (Comirnaty®) 
and COVID-19 mRNA Vaccine Moderna® by Moderna have been licensed in Switzerland and roll-out 
of vaccines has started. 
In phase III licensing trials of both vaccines, vaccine efficacy of 95% and 94% were found and both 
vaccines appeared to be save. However, few individuals with HIV infection were included in both trials 
and no solid organ recipients were enrolled in the trials. 
Data on vaccine efficacy, induced immune response and safety in immunocompromised individuals with 
chronic HIV infection or solid organ transplantation is missing. We intend to close this information gap 
with a pilot trial, which represents the first-sub-study trial of the established trial platform that is linked 
and nested into the existing prospectively collected data structure of the Swiss HIV Cohort Study (SHCS) 
and the Swiss Transplant Cohort Study (STCS). 
 
Objectives and Endpoints: 
To investigate the operability of a platform trial that is nested into two existing cohort studies and 
compare immune response, safety and clinical efficacy of the first two mRNA vaccines (Comirnaty® by 
Pfizer / BioNTech and COVID-19 mRNA Vaccine Moderna®, by Moderna) in immune compromised 
patients in the Swiss HIV and Swiss Transplant Cohort studies. 
 
Feasibility endpoints: 
We refer to the master protocol 
 
Immunological endpoints (primary endpoint) 
- 
Immune response (pan-Ig antibodies against the receptor binding domain (RBD) in the S1 
subunit of the spike protein (pan-Ig anti–S1-RBD) of SARS-CoV-2. 
- 
Newly PCR-confirmed asymptomatic SARS-CoV-2 infection 
Clinical Endpoints 
- 
Newly PCR-confirmed symptomatic SARS-CoV-2 infection 
- 
Severe COVID-19 infection, hospitalization due to COVID-19 or death 
- 
COVID-19 burden of diseases (BOD) 
- 
Patient reported asymptomatic or symptomatic infections of household members. 
Safety endpoints 
- 
Adverse events from vaccines and 
- 
Serious adverse events 
 
Overall Design: 
Multicenter randomised controlled, open-label, 2-arm sub-study pilot trial of a platform trial nested in 
two national cohorts 
 
Number of Participants enrolled: 
Eligible individuals are screened and flagged in both cohorts according to priority vaccination 
recommendations by the BAG. We will randomise 380 patients from both cohorts (recruitment of 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 19 of 44 
 
patients from the Swiss Transplant Cohort Study will be limited to kidney and lung transplant recipients. 
These patients will be randomised to vaccination with Comirnaty® or the COVID-19 mRNA Vaccine 
Moderna®. 
Intervention Groups and Duration: 
Participants of the Swiss HIV Cohort and Swiss Transplant Cohort Studies with informed consent and 
no exclusion criteria will be centrally randomised via the trial platform to vaccination with mRNA vaccines 
COVID-19 mRNA Vaccine Moderna® or Comirnaty® (Pfizer / BioNTech) at day 0 with booster vaccines 
at day 21 and day 28, respectively. Antibodies against Sars-Cov-2 will be measured at baseline and 12 
weeks with the Elecsys® anti-SARS_CoV_2 S and N (Roche Rotkreuz Siwtzerland) and ABCORA2.0 
(IMV) assays. Vaccine related AE will be assessed at 12 weeks. SAE and asymptomatic or symptomatic 
Sars-Cov-2 infection (PCR confirmed) and hospitalisation, ICU admission, or death from any cause will 
be recorded at 48 weeks within the clinical trial platform and by routine cohort data collection. 
 
 
STUDY SCHEDULE 
 
STUDY PERIOD 
Eligibility 
Enrolment, 
randomisation 
& vaccination 
Post-randomisation 
TIMEPOINT 
Approximately 
-12 weeks 
Day 0 
Week 4 
Week 
12 (±7 
days) 
Week 48 
(±7 
days) 
Continuous 
follow-up 
in 
the    frame    of 
the cohort 
ENROLMENT: 
Eligibility screena 
Eligibility assessment 
Informed consent 
Allocation 
Xa 
X 
Xa 
X b 
INTERVENTIONS: 
Intervention COVID-19mRNA 
Vaccine Moderna® 
X 
X 
Control Comirnaty® 
(Pfizer/BioNTntech vaccine) 
X 
X 
ASSESSMENTS: 
BASELINE    VARIABLES    (will    be 
exported from routine cohort data) 
Baseline blood sample 
X 
IGG neutralizing antibodies post 
randomisation 
but 
prior 
to 
vaccination 
X 
CLINICAL OUTCOMES: 
Xe 
Xe 
- Immune response IgG neutralizing 
antibodies 
X 
xc 
-  Newly  confirmed  asymptomatic 
SARS-CoV-2 infection 
xc 
xc,d 
x d 
-Newly 
confirmed 
symptomatic 
SARS-CoV-2 infection 
xc 
xc,d 
x d 
- Severe COVID-19 infection with 
respiratory failure, evidence of 
shock, organ failure, admission to 
ICU, or death 
xc 
xc,d 
x d 
- Adverse events from vaccines 
xc 
-Serious adverse events 
xc,d 
xc 
xc,d 
x d 
- PCR confirmed symptomatic 
infections of household members 
xc 
xc.d 
x d 
aContinuous assessment and selection from routinely collected cohort data 
bEnrolment and concealed allocation of patients with informed consent will be performed during the same visit when the study is 
explained to the patient, or, if preferred, during a separate arranged study visit. 
cAssessed in separate data entry form for the trial 
d Assessed by routine data collection from cohort data base 
eBaseline blood samples will be taken from previous cohort visits (no longer than 6 months) or during cohort and randomisation 
visits at day 0. 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 20 of 44 
 
1. STUDY ADMINISTRATIVE STRUCTURE 
 
A safety committee consisting of two infectiologists not otherwise involved in the trial and a biostatistician 
will be formed to oversee patient enrolment and efficacy and safety issues with respect to vaccines used 
during the pilot trial. 
 
1.1 Sponsor-Investigator 
 
University Hospital Basel 
Prof. Heiner C. Bucher MD, MPH 
Basel Institute for Clinical Epidemiology & Biostatistics 
University Hospital Basel 
Spitalstrasse 12 
4056 Basel 
Switzerland 
Phone: +41 (0)61 328 6101 
Email: heiner.bucher@usb.ch 
 
1.2 Local Principal Investigator(s) 
Dr. Marcel P. Stoeckle 
Basel HIV Cohort 
Division of Infectious Diseases and Hospital Epidemiology 
University Hospital Basel 
Petersgraben 4 
4031 Basel 
 
Prof. Huldrych Günthard 
Zürich HIV Cohort 
Division of Infectious Diseases and Hospital Epidemiology 
Universitätsspital Zürich 
Rämistrasse 100 
8091 Zürich 
 
Dr. Anna Lena Eichenberger 
Bern HIV Cohort 
Universitätsklinik für Infektiologie 
Freiburgstrasse 16p, Haus 5, Stock E 
3010 Bern 
 
PD Dr. Macé Schuurmans 
STCS Zürich (Lung-transplantations) 
Universitätsspital Zürich 
Rämistrasse 100 
8091 Zürich 
 
PD Dr Oriol Manuel 
STCS CHUV Lausanne (Solid organ transplantations) 
CHUV 
Service des maladies infectieuses 
Rue du Bugnon 46 
CH-1011 Lausanne, Vaud 
 
Prof. Matthias Cavassini 
CHUV Lausanne HIV 
CHUV 
Service des maladies infectieuses 
Rue du Bugnon 46 
CH-1011 Lausanne, Vaud 
 
Prof. Thomas Müller 
STCS (Kidney) Zürich 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 21 of 44 
 
Klinik für Nephrologie 
Universitätsspital Zürich 
Rämistrasse 100 
8091 Zürich 
 
Prof. Michael Tamm 
STCS (Lung) Basel 
Universitätsspital Basel 
Pneumologie 
Petersgraben 4 
4051 Basel 
 
Prof. Michael Dickenmann 
STCS (Kidney) Basel 
Universitätsspital Basel 
Transplantationsimmunologie & Nephrologie 
Petersgraben 4 
4051 Basel 
 
 
1.3 Statistician ("Biostatistician") 
Dr. Frédérique Chammartin 
Basel Institute for Clinical Epidemiology & Biostatistics 
University Hospital Basel 
Spitalstrasse 12 
4056 Basel 
Switzerland 
Email: frederique.chammartin@usb.ch 
 
 
1.4 Laboratory 
Dr. sc.nat. Dr.med. Irene A. Abela 
Institut für medizinische Virologie 
Universität Zürich 
Winterthurerstrasse 190 
8057 Zürich 
 
 
1.5 Co-investigators 
Dr. Speich, Benjamin 
PD Dr. med. Hemkens, Lars G. 
Prof. Matthias Briel MD, PhD, MSc 
Basel Institute for Clinical Epidemiology and Biostatistics 
Departement Klinische Forschung 
University Hospital Basel 
Switzerland 
 
PD Michael Koller, PhD 
Transplantationsimmunologie und Nephrologie, Datenzentrum Swiss Transplant Cohort Study 
Universitätsspital Basel und Universität Basel 
Spitalstrasse 12 
4031 Basel 
Switzerland 
Email: Michael.koller@usb.ch 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 22 of 44 
 
Prof. Nicolas Müller MD 
Klinik für Infektionskrankheiten und Spitalhygiene 
Universitätsspital Zürich und Universität Zürich 
Rämistrasse 100 
8091 Zürich 
Email: nicolas.mueller@usz.ch 
 
Prof. Huldyrch Günthard MD PhD 
Universitätsspital Zürich und Universität Zürich 
Rämistrasse 100 
8091 Zürich 
Email: huldrych.guenthard@usz.ch 
Spitalstrasse 12 
4056 Basel 
Switzerland 
 
Prof. Andri Rauch MD PhD 
Inselspital, Universitätsspital Bern 
Freiburgstr. 16p 
3010 Bern 
Email: andri.rauch@insel.ch 
 
 
1.6 Monitoring institution 
Central monitoring of data entry into the trial platform and cohort database will be done within the 
routine procedures by the central and local cohort data managers and the biostatistician responsible 
for the sub-study pilot trial. 
 
 
1.7 Data Safety Monitoring Committee 
An independent data safety monitoring board (IDSMB) will be established which will be advisory to the 
Trial Committee that constitutes of the PI and the co-investigators. The IDSMB will be regularly informed 
about any safety aspects and on serious adverse events from vaccinations from the first sub-study 
protocol and it will provide the primary investigator and the co-investigators with recommendations about 
the further conduct of the trial. 
For further details we refer to the master protocol. 
 
1.8 Any other relevant Committee, Person, Organisation, Institution 
Not applicable. 
 
1.9 Authors contributions 
Heiner Bucher (HB); Michael Koller  (MK); Matthias Briel (MB); Lars Hemkens (LG); Frédérique 
Chammartin (FC); and Benjamin Speich (BS) designed the study. Nicolas Müller (NM); Huldyrch 
Günthard (HG); Andri Rauch (AR); Daniel Smith (DS) and Katharina Kusejko (KK) gave scientific input. 
HB wrote the first draft of the sub-protocol. All authors critically revised and approved the final version 
of the study protocol. HB acquired funding for the trial. 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 23 of 44 
 
2. ETHICAL AND REGULATORY ASPECTS 
 
We refer to the master protocol. 
 
2.1 Study registration 
The pilot trial is registered with the U.S. National Institutes of Health (www.clinicaltrials.gov) under 
NCT04805125. The pilot-trial will also be registered with the Koordinationsstelle Forschung am Mensch 
(kofam). 
 
2.2 Categorisation of study 
Category A. This sub-study pilot trial will use vaccines against SARS-CoV-2, which have been licensed 
by Swissmedic in accordance with the prescribing information approved by Swissmedic, and which - by 
guidelines from the BAG and Kommission für Impffragen - may be used in immune suppressed 
individuals when considering the individual benefits and risks. 
 
2.3 Competent Ethics Committee (CEC) 
We refer to the master protocol. 
 
2.4 Competent Authorities (CA) 
We refer to the master protocol. 
 
2.5 Ethical Conduct of the Study 
We refer to the master protocol. 
 
2.6 Declaration of interest 
We refer to the master protocol. 
 
2.7 Patient Information and Informed Consent 
We refer to the master protocol. 
 
2.8 Participant privacy and confidentiality 
We refer to the master protocol. 
 
2.9 Early termination of the study 
The Sponsor-Investigator may terminate the pilot trial sub-study prematurely according to certain 
circumstances, for example: 
• 
ethical concerns, 
• 
insufficient participant recruitment, 
• 
when the safety of the participants is doubtful or at risk, 
• 
alterations in accepted clinical practice that make the continuation of a clinical trial unwise, 
• 
evidence of harm from investigated vaccines 
 
2.10 Protocol amendments 
We refer to the master protocol. 
 
 
3. BACKGROUND AND RATIONALE 
 
3.1 Background and Rationale 
A new highly contagious corona virus SARS-CoV-2 has emerged in late 2019 in Wuhan, China, and 
caused in a two month period a pandemic with the highest disease burden in elderly and people with 
pre-existing medical conditions (1-3). After nearly one year into the epidemic over 0.5 million infections, 
over 21’000 hospitalisations, and over 8`200 deaths due to SARS-CoV-2 have been recorded in 
Switzerland (January 21, 2021). The highest burden of severe Covid-19 infections and deaths is in the 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 24 of 44 
 
elderly and in individuals with comorbidities known to present risk factors for a severe infection. Since 
January 12, 2021 two mRNA vaccines against Sars-CoV-2 by Pfizer / BioNTech (Comirnaty®) and 
COVID-19 mRNA Vaccine Moderna® by Moderna have been licensed in Switzerland and role-out of 
vaccines has started (4, 5). 
In phase III licensing trials of both vaccines which were both submitted as emergency use authorisation 
(EUA) to FDA with parallel submission to Swissmedic, vaccine efficacy of 95% and 94% were found 
and both vaccines appeared to be safe. However, estimates of vaccine efficacy were imprecise and with 
large confidence intervals in the subgroups of individuals most at risk of complications from SARS-CoV- 
2 infection like the elderly and those with comorbidities. Likewise, data on immune response overall and 
in subgroups is not yet available (6, 7). 
In particular very few individuals in both trials with HIV infection were included (with no information on 
the CD4 cell count at the time point of vaccination and no solid organ recipients were allowed in the 
trials). 
Data on vaccine efficacy, induced immune response and safety in immunosuppressed individuals with 
chronic HIV infection or solid organ transplantation is missing. We intend to close this information gap 
with a pilot trial which represents the first sub-study trial of the established trial platform that is linked 
and nested into the existing prospectively collected data structure the two most prominent cohort studies 
in Switzerland, the Swiss HIV Cohort Study (SHCS) and the Swiss Transplant Cohort Study (STCS) (8, 
9). 
 
3.2 Investigational Product (treatment, device) and Indication 
 
3.3 Preclinical Evidence 
We summarize and cite from the published study and online submission documents handed-in to FDA 
and only cite relevant early safety and efficacy data. For all preclinical data we refer to the summaries 
in the online submission documents (10, 11). 
 
 
Pfizer / BioNTech conducted several pilot studies to test the immunogenicity and safety of BNT162- 
01. All these studies are ongoing. BNT162-01 is an ongoing dose finding escalating study with 
investigation of immunogenicity in 60 adults aged 18-55 years (Phase I). C4591001 is an ongoing phase 
I II III observer blind placebo controlled trial where in phase I 90 individuals are randomised in a 4 to 1 
ratio within each dose and age group of adults aged 18-55 and 65 -85 years and vaccine doses of 10, 
20, and 30 µg. Phase II randomised 360 individuals 1:1 to vaccine (30 µg) vs placebo in two age groups 
18-55 and 65-85 years of age. Phase III randomised approximately 44’000 participants and includes all 
phase II participants in a 1:1 ratio vaccine (30 µg) vs placebo in three age groups 12-15 years, 16-55 
years and >55 years of age. 
 
Study BNT162-01 by Pfizer / BioNTech is the ongoing, Phase 1 dose level-finding study, in which 
healthy adults 18 to 55 years of age all receive active vaccine. This study is evaluating the safety and 
immunogenicity of several different candidate vaccines at various dose levels. The data for BNT162b2 
30 μg were available from 58 participants completed BNT162b2 dosing in the Phase 1 part of the study. 
The reasons for study discontinuation by each of 2 participants were AE (10 μg group) and participant 
withdrawal (1 μg group). 
 
After administration of Dose 1 and prior to administration of Dose 2, BNT162b2 showed modest 
increases in SARS-CoV-2 neutralizing geometric mean titers (GMTs) over baseline, followed by a 
boost effect after dose 2 that was most pronounced at the 30 μg dose level. At Day 50 post first 
vaccination, the neutralizing GMT in the 10 μg and 30 μg BNT162b2 participants remained above the 
GMT in the human convalescent serum (HCS). Further evaluation of antibody persistence is ongoing. 
 
In the C4591001 Phase 1 study BNT162b2 was administered to 45 younger participants among 
whom 42% were male and 58% were female, 87% were White, 4% were Hispanic/Latino, with a 
median 37 years of age. BNT162b2 was administered to 45 older participants among whom 38% 
were male and 62% were female, 100% were White, none were Hispanic/Latino, with a median 68 
years of age. All participants received both vaccine doses and none discontinued the study as of the 
data cutoff date of 14 November 2020, after approximately 4 months of follow-up. 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 25 of 44 
 
In the Phase 1 portion of Study C4591001, after administration of Dose 1 and prior to administration of 
Dose 2, BNT162b2 showed modest increases in SARS-CoV-2 neutralizing GMTs over baseline across 
dose levels and younger and older groups. Overall, BNT162b2 elicited higher antigen-binding and 
neutralizing responses in younger participants than in older participants. The boost effect after 
receiving Dose 2 was most pronounced at the 30 μg dose level for older participants. GMTs measured 
at 7 days after Dose 2 for BNT162b2 at the 30 μg dose were 360.9 in the younger group and 155.7 in 
the older group. When compared to an HCS panel GMT of 94, the GMT for the younger group was 
approximately 3.8-times that of HCS and for the older group was approximately 1.7-times that of 
HCS.18 By 1 month after Dose 2, GMTs were generally stable and remained approximately 1.6- to 
1.9-times that of HCS. 
In summary, based on immunogenicity results from Phase 1 participants in Study C4591001, 
BNT162b2 elicited robust SARS-CoV-2 neutralization and S1-binding IgG antibody levels in younger 
healthy adults 18 to 55 years of age, and in older healthy adults 65 to 85 years of age. Immune 
responses were generally stronger in the  younger group than in the older group. SARS-CoV-2 
neutralizing titers GMTs were higher than those observed in an HCS18 panel from people recovered 
from COVID-19. Responses were evident after the first dose and substantially boosted after the second 
dose, supporting the need for a 2-dose vaccination series. 
 
Most participants who received both doses of BNT162b2 had strong SARS-CoV-2 S protein-specific 
CD4+ (39/39, 100%) and CD8+ (35/39, 89.7%) T cell responses. These T cell responses were 
directed against different parts of the antigen including epitopes in the receptor-binding domain 
(RBD), indicating the induction of multi-epitope responses by BNT162b2. 
Dosing twice with BNT162b2 led to a substantial increase in the incidence and magnitude of T cell 
responses. Overall, the mean fraction of S-specific CD4+ and CD8+ T cells was substantially higher 
(eg, S protein sub-pool 1 IFNγ CD8+ response of 30 μg dosed participants was 12.5-fold above) than 
that observed in 18 individuals who recovered from COVID-19. 
 
Fore safety data on phase I studies see below. 
 
 
The mRNA-1273 vaccine manufactured by Moderna, encodes the S-2P antigen, consisting of the 
SARS-CoV-2 glycoprotein with a transmembrane anchor and an intact S1–S2 cleavage site. S-2P is 
stabilized in its prefusion conformation by two consecutive proline substitutions at amino acid positions 
986 and 987, at the top of the central helix in the S2 subunit. The lipid nanoparticle capsule composed 
of four lipids is formulated in a fixed ratio of mRNA and lipid. 
The vaccine was tested in a phase 1 dose finding open labeled study in 45 healthy adults, 18 to 55 
years of age, who received two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 μg, 100 
μg, or 250 μg. There were 15 participants in each dose group. The vaccine was administered as a 0.5- 
ml injection in the deltoid muscle on days 1 and 29; follow-up visits were scheduled for 7 and 14 days 
after each vaccination and on days 57, 119, 209, and 394. The dose-escalation plan specified the 
staggered enrollment of patients in the three dose groups allowing for additional enrolement when no 
halting rules were met. Participants recorded local and systemic reactions, using a memory aid, for 7 
days after each vaccination. 
No serious adverse events were noted, and no prespecified trial halting rules were met. One 
participant in the 25-μg group was withdrawn because of an unsolicited adverse event, transient 
urticaria, judged to be related to the first vaccination. After the first vaccination, solicited systemic 
adverse events were reported by 5 participants (33%) in the 25-μg group, 10 (67%) in the 100-μg 
group, and 8 (53%) in the 250-μg group; all were mild or moderate in severity. Solicited systemic 
adverse events were more common after the second vaccination and occurred in 7 of 13 participants 
(54%) in the 25-μg group, all 15 in the 100-μg group, and all 14 in the 250-μg group, with 3 of those 
participants (21%) reporting one or more severe events. After the second vaccination, no participants 
in the 25-μg group, 6 (40%) in the 100-μg group, and 8 (57%) in the 250-μg group reported fever; one 
of the events (maximum temperature, 39.6°C) in the 250-μg group was graded severe. Local adverse 
events, when present, were nearly all mild or moderate, and pain at the injection site was common 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 26 of 44 
 
Binding antibody responses were assessed against S-2P and the isolated receptor-binding domain, 
located in the S1 subunit by ELISA. Vaccine-induced neutralizing activity was assessed by a 
pseudotyped lentivirus reporter single-round-of-infection neutralization assay (PsVNA) and by live 
wild-type SARS-CoV-2 plaque-reduction neutralization testing (PRNT) assay. ELISA and PsVNA were 
performed on specimens collected from all participants on days 1, 15, 29, 36, 43, and 57. For the 
PsVNA results were only available for the day 1 and day 43 time points in the 25-μg and 100-μg dose 
groups. For comparison of the participants’ immune responses with those induced by SARS-CoV-2 
infection, 41 convalescent serum specimens were also tested. 
T-cell responses against the spike protein were assessed by an intracellular cytokine–staining assay, 
performed on specimens collected at days 1, 29, and 43. Results were available only for the 25-μg and 
100-μg dose groups. 
Binding antibody IgG geometric mean titers (GMTs) to S-2P increased rapidly after the first   
vaccination and all participants seroconverted by day 15 Dose-dependent responses to the first and 
second vaccinations were found. Receptor-binding domain–specific antibody responses were similar  
in pattern and magnitude. For both assays, the median magnitude of antibody responses after the first 
vaccination in the 100-μg and 250-μg dose groups was similar to the median magnitude in 
convalescent serum specimens, and in all dose groups the median magnitude after the second 
vaccination was in the upper quartile of values in the convalescent serum specimens. The S-2P ELISA 
GMTs at day 57 (299,751 [95% CI, 206,071 to 436,020] in the 25-μg group, 782,719 [95% CI, 619,310 
to 989,244] in the 100-μg group, and 1,192,154 [95% CI, 924,878 to 1,536,669] in the 250-μg group) 
exceeded that in the convalescent serum specimens (142,140 [95% CI, 81,543 to 247,768]). 
No participant had detectable PsVNA responses before vaccination. After the first vaccination, PsVNA 
responses were detected in less than half the participants, and a dose effect was seen and after the 
second vaccination PsVNA responses were identified in serum samples from all participants. The 
lowest responses were in the 25-μg dose group, with a geometric mean ID50 of 112.3 (95% CI, 71.2  
to 177.1) at day 43; the higher responses in the 100-μg and 250-μg groups were similar in magnitude 
(geometric mean ID50, 343.8 [95% CI, 261.2 to 452.7] and 332.2 [95% CI, 266.3 to 414.5], 
respectively, at day 43). These responses were similar to values in the upper half of the distribution of 
values for convalescent serum specimens. Before vaccination, no participant had detectable 80% live- 
virus neutralization at the highest serum concentration tested (1:8 dilution) in the PRNT assay. At day 
43, wild-type virus–neutralizing activity capable of reducing SARS-CoV-2 infectivity by 80% or more 
(PRNT80) was detected in all participants, with geometric mean PRNT80 responses of 339.7 (95% CI, 
184.0 to 627.1). 
The 25-μg and 100-μg doses elicited CD4 T-cell responses with expression of Th1 cytokines (tumor 
necrosis factor α > interleukin 2 > interferon γ), and minimal type 2 helper T-cell (Th2) cytokine 
expression (interleukin 4 and interleukin 13). CD8 T-cell responses to S-2P were detected at low levels 
after the second vaccination in the 100-μg dose group. 
 
3.4 Clinical Evidence to Date 
We summarize and cite from the published study and submission documents handed in to FDA (10, 
11). 
 
In response to the global health crisis, Pfizer and BioNTech submitted November 20, 2020 an 
Emergency Use Authorization (EUA) application (EUA request 27034) for the COVID-19 Vaccine 
(BNT162b2) to FDA. The vaccine is based on a SARS-CoV-2 spike glycoprotein (S) antigen encoded 
by RNA formulated in lipid nanoparticles (LNPs). In parallel submission to EMA and Swissmedic were 
done and Swissmedic licensed the vaccine on December 19, 2020. 
 
The EUA request by Pfizer / BioNTech includes safety and efficacy data from approximately 38,000 
participants randomised 1:1 to receive either vaccine or placebo with a median of 2 months of follow-up 
after Dose 2 of the 2-dose vaccine regimen in Study C4591001 show that BNT162b2 at 30 µg was safe 
and well-tolerated in participants ≥16 years of age (6, 10). 
In 37,706 participants, the duration of follow-up was ≥2 months post Dose 2 for 50.6% of participants. 
Duration of follow up was ≥1 month post Dose 2 for 91.6% of participants. Median age was 52 years 
and 50.6% of participants were male. The younger and older age groups were 57.8% and 42.2% of 
participants, respectively. Obese participants made up 35.1% of this safety population. Across both 
treatment groups, 20.5% had any comorbidity (per the Charlsson Comorbidity Index). The most 
frequently reported comorbidities were diabetes (with and without chronic complications, 8.4%) and 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 27 of 44 
 
pulmonary disease (7.8%) and were reported at similar frequencies in each group. More participants 
had comorbidities in the older population (31.1%) than the younger population (12.8%), including 
diabetes (14.6% and 3.8%), malignancy (7.4% and 1.0%), and pulmonary disease (8.8% and 7%). 
Overall, 0.3% of participants were HIV-positive. 
Overall, 0.2% of randomised participants did  not receive study vaccine.  A small percentage of 
participants discontinued study vaccine after Dose 1 and before Dose 2 (0.6%) overall. The most 
frequently reported reasons for discontinuation included: no longer meets eligibility criteria (0.3% 
BNT162b2; 0.4% placebo; the most common reasons were previous clinical or microbiological diagnosis 
of COVID-19), withdrawal by participant, and AE. Withdrawals due to AE were reported for 0.1% of 
participants in both treatment groups. 
All participants in Phase 1 and a subset of at least 6000 participants in Phase 2/3 were planned to 
record local reactions, systemic events, and antipyretic/pain medication usage for 7 days, following 
administration of study intervention using an electronic diary (ediary) from Day 1 through Day 7 after 
each dose. 
 
For any Phase 3 participants who were not in the reactogenicity subset, local reactions and systemic 
events consistent with reactogenicity were detected and reported as AEs. 
Phase 2/3 AE data were analyzed for the safety population overall and by: Evidence of prior SARS- 
CoV-2 infection at baseline per nucleic acid amplification test (NAAT) or N-binding antibody assay and 
by subgroup factors (ie, age, sex, race, ethnicity). 
 
Immunogenicity was  evaluated in Phase 1 using a SARS-CoV-2 serum neutralization assay to 
determine titers and a SARS-CoV-2 S1 binding IgG direct Luminex immunoassay to determine antibody 
binding levels. Fold rises were also assessed. Only qualified assays were used. 
Immunogenicity data were analyzed and reported using descriptive summary 
statistics of 
GMTs/geometric mean concentrations (GMCs) and geometric mean fold-rises (GMFRs) for the 
evaluable immunogenicity population. 
 
Efficacy was assessed based on confirmed cases of COVID-19, for which the case onset date was the 
date that symptoms were first experienced by the participant and the cases met evaluable criteria. For 
participants with multiple confirmed cases, only the first case contributed to the VE calculations. 
Evaluable cases consisted of a positive virological test plus at least one COVID-19 symptom 
 
First primary efficacy endpoint in the phase III trial was COVID-19 incidence per 1000 person-years of 
follow-up in participants without serological or virological evidence of past SARS-CoV-2 infection 
before and during vaccination regimen – cases confirmed ≥7 days after Dose 2. The second primary 
endpoint was COVID-19 incidence per 1000 person-years of follow-up in participants with and without 
evidence of past SARS-CoV-2 infection before and during vaccination regimen – cases confirmed ≥7 
days after Dose 2. 
A pre-specified interim analysis of the first primary efficacy endpoint was conducted after accrual of 94 
COVID-19 cases. Among participants included in the evaluable efficacy population at the time of the 
interim analysis, 32,279 participants overall (16,061 in the BNT162b2 group and 16,218 in the placebo 
groups) did not have evidence of prior infection with SARS-CoV-2 before and during vaccination 
regimen. 
Among participants without evidence of SARS-CoV-2 infection before and during vaccination regimen, 
VE against confirmed COVID-19 occurring at least 7 days after Dose 2 was 95.0%, with 8 COVID-19 
cases in the BNT162b2 group compared to 162 COVID-19 cases in the placebo group. The 95% 
credible interval for the VE was 90.3% to 97.6%, indicating that the true VE is at least 90.3% with a 
97.5% probability given the observed data. 
Among participants with and without evidence of SARS-CoV-2 infection before and during vaccination 
regimen, VE against confirmed COVID-19 occurring at least 7 days after Dose 2 was 94.6%, with 9 and 
169 cases in the BNT162b2 and placebo groups respectively. The posterior probability of >99.99% for 
the true VE greater than 30% met the pre-specified success criterion of >98.6% for this endpoint. The 
95% credible interval for the VE was 89.9% to 97.3%, indicating that the true VE is at least 89.9% with 
a 97.5% probability given the available data. 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 28 of 44 
 
In total 37,586 participants were included in the AE analyses presented in the sections below. 
 
Results for all enrolled participants (N=43,252 participants) who had variable follow up from Dose 1 to 
the data cutoff date of 14 November 2020 are also presented below. For the 37,586 participants who 
had a median of at least 2 months of follow-up after Dose 2 (including those analyzed in Phase 2) the 
numbers of overall participants who reported at least 1 AE and at least 1 related AE were higher in the 
BNT162b2 group as compared with the placebo group. This trend continued to be seen through the 
data cutoff date for all enrolled participants (43,252 participants). Few participants in either group had 
severe AEs, SAEs, or AEs leading to study withdrawal. The incidences of deaths reported were low and 
similar in the BNT162b2 (1; 0.0%) and placebo (2; 0.0%) groups. 
In the younger age group, the number of participants who reported at least 1 AE from Dose 1 to 1 
month after Dose 2 was 3177 (29.3%) and 1427 (13.2%) in the BNT162b2 and placebo groups, 
respectively. In the older age group, the number of participants who reported at least 1 AE from Dose 
1 to 1 month after Dose 2 was 1894 (23.8%) and 929 (11.7%) in the BNT162b2 and placebo groups, 
respectively. Among the 37,586 participants, no clinically meaningful differences in AEs by category 
were observed by age, sex, race/ethnicity, or baseline SARS-CoV-2 status subgroups. 
 
 
The EUA request by Moderna includes safety and efficacy data from an ongoing Phase 3 randomised, 
double-blinded and placebo-controlled trial of mRNA-1273 in approximately 30,400 participants (7, 
11). The primary efficacy endpoint was the reduction of incidence of COVID-19 among participants 
without evidence of SARS-CoV-2 infection before the first dose of vaccine in the period after 14 days 
post-dose 2. In an interim analysis conducted using a data cut-off of November 7, 2020, a total of 27,817 
participants randomised 1:1 to vaccine or placebo with a median 7 weeks of follow-up post-dose 2 were 
included in the per-protocol efficacy analysis population of participants without evidence of SARS-CoV- 
2 infection prior to vaccination. Efficacy in preventing confirmed COVID-19 occurring at least 14 days 
after the second dose of vaccine was 94.5.0% (95% CI 86.5%, 97.8%) with 5 COVID-19 cases in the 
vaccine group and 90 COVID-19 cases in the placebo group. Subgroup analyses of the primary efficacy 
endpoint showed similar efficacy point estimates across age groups, genders, racial and ethnic groups, 
and participants with medical comorbidities associated with high risk of severe COVID-19. Secondary 
efficacy analyses suggested benefit of the vaccine in preventing severe COVID-19 (11 protocol-defined 
severe COVID-19 cases in the placebo group vs. 0 cases in the vaccine group), in preventing COVID- 
19 following the first dose, and in preventing COVID-19 in individuals with prior SARS-CoV-2 infection, 
although available data for some of these outcomes did not allow for firm conclusions. Efficacy data 
from the final scheduled analysis of the primary efficacy endpoint (data cut-off of November 21, 2020, 
with a median follow-up of >2 months post-dose 2) demonstrated a VE of 94.1% (95% CI 89.3%, 96.8%), 
with 11 COVID-19 cases in the vaccine group and 185 COVID-19 cases in the placebo group and was 
consistent with results obtained from the interim analysis. The VE in this analysis when stratified by age 
group was 95.6% (95% CI: 90.6%, 97.9%) for participants 18 to < 65 years of age and 86.4% (95%CI: 
61.4%, 95.5%) for participants ≥ 65 years of age. A final secondary efficacy analysis also supported 
efficacy against protocol-defined severe COVID-19, with 30 cases in the placebo group vs. 0 cases in 
the vaccine group. 
 
Safety data from a November 11, 2020 interim analysis of approximately 30,350 participants ≥18 years 
of age randomised 1:1 to vaccine or placebo with a median of 7 weeks of follow-up after the second 
dose supported a favorable safety profile, with no specific safety concerns identified that would preclude 
issuance of an EUA. These safety data are the primary basis of FDA’s safety review. On December 7, 
2020, the Sponsor submitted additional follow-up data from these participants with a cut-off of November 
25, 2020, which represents a median of 9 weeks (>2 months) of follow-up post-dose 2. Key safety data 
from this later submission, including death, other serious adverse events, and unsolicited adverse 
events of interest were independently verified and confirmed not to change the safety conclusions from 
the interim safety analysis. 
 
The most common solicited adverse reactions associated with mRNA-1273 were injection site pain 
(91.6%), fatigue (68.5%), headache (63.0%), muscle pain (59.6%), joint pain (44.8%), and 6 Moderna 
COVID-19 Vaccine VRBPAC Briefing Document chills (43.4%); severe adverse reactions occurred in 
0.2% to 9.7% of participants, were more frequent after dose 2 than after dose 1, and were generally 
less frequent in participants ≥65 years of age as compared to younger participants. Among unsolicited 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 29 of 44 
 
adverse events of clinical interest, which could be possibly related to vaccine, using the November 25, 
2020 data cutoff, lymphadenopathy was reported as an unsolicited event in 173 participants (1.1%) in 
the vaccine group and 95 participants (0.63%) in the placebo group. Lymphadenopathy (axillary swelling 
and tenderness of the vaccination arm) was a solicited adverse reaction observed after any dose in 
21.4% of vaccine recipients < 65 years of age and in 12.4% of vaccine recipients ≥ 65 years of age, as 
compared with 7.5% and 5.8% of placebo recipients in those age groups, respectively. There was a 
numerical imbalance in hypersensitivity adverse events across study groups, with 1.5 of vaccine 
recipients and 1.1% of placebo recipients reporting such events in the safety population. There were no 
anaphylactic severe hypersensitivity reactions with close temporal relation to vaccine. Throughout the 
safety follow-up period there were three reports of facial paralysis (Bell’s palsy) in the vaccine and one 
in the placebo group. There were no other notable patterns of numerical imbalances between treat 
groups for specific categories of adverse events (including other neurologic, neuroinflammatory, and 
thrombotic events) that would suggest a causa relationship to mRNA-1273. 
 
The frequency of serious adverse events was low (1.0% in the mRNA-1273 arm and 1.0% in the placebo 
arm), without meaningful imbalances between study arms. The most common SAEs in the vaccine 
group which were numerically higher than the placebo group were myocardial infarction (0.03%), 
cholecystitis (0.02%), and nephrolithiasis (0.02%), although the small numbers of cases of these events 
do not suggest a causal relationship. The most common SAEs in the placebo arm which was numerically 
higher than the vaccine arm, aside from COVID-19 (0.1%), were pneumonia (0.05%) and pulmonary 
embolism (0.03%). 
 
With the exception of more frequent, generally mild to moderate reactogenicity in participants <65 years 
of age, the safety profile of mRNA-1273 was generally similar across age groups, genders, ethnic and 
racial groups, participants with or without medical comorbidities, and participants with or without 
evidence of prior SARS-CoV-2 infection at enrolment. 
 
3.5 Dose Rationale / Medical Device: Rationale for the intended purpose in 
study (pre-market MD) 
(ICH/E6 6.2.4; SPIRIT #6a) 
ICH: Description of and justification for the route of administration, dosage, dosage regimen, and 
treatment period(s). 
Application of vaccines in the intervention and comparator arm will be done according to the product 
specifications by the producers and Swissmedic using the dosing and vaccination schedule as by the 
recommendations by the producer and the Schweizerisches Bundesamt für Gesundheit. 
 
The vaccine COVID-19 mRNA Vaccine Moderna® is licensed to be used in adults (older than 18 years) 
and is to be applied by intramuscular infections. The proposed dosing is 30 microgram on day 0 and 
day 28 and the vaccine was licensed January 12, 2021 by Swissmedic (11). 
. 
 
3.6 Explanation for choice of comparator (or placebo) 
(SPIRIT #6b) 
The Pfizer / BioNTech COVID-19 vaccine, BNT162b2 (30 µg) Comirnaty®, is administered 
intramuscularly (IM) as a series of two 30 µg doses of the diluted vaccine solution (0.3 mL each) 
according to the following schedule: a single dose followed by a second dose, waiting at least 21 days 
later (recommended: 28 days in Switzerland) and the vaccine was licensed by Swissmedic December 
19, 2021 (12). 
 
 
3.7 Risks / Benefits 
(ClinO, Appendix 4, 3.5; Art 25d2; ICH/E6 6.2.3; SPIRIT #6a; MD: ISO 14155 Annex A & ISO 14971) 
ICH: Summary of the known and potential risks and benefits, if any, to human subjects. 
In December 2020 between 80 to 100 individuals in Switzerland died per day from Covid-19. Actual 
rates are lower following more stringent public health measures with a partial lock-down, but rising 
mutant infections with higher transmission rates are of concern. Introduction of vaccines is the only 
valid strategy to confine the pandemic by inducing a sufficiently high herd immunity. At the forefront of 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 30 of 44 
 
the vaccine strategy by BAG is the vaccination of the elderly and frail population suffering from 
comorbidity. The current trials addressed the very important issue of vaccine induced immunogenicity 
and safety data in immune-compromised individuals who were not or only to a very limited extend 
included into the ongoing phase III vaccine trials by Pfizer / BioNTech and Moderna. 
The so far existing evidence for both vaccines to be compared in the current trial show strong immune 
responses in the short observation periods of roughly 60 days, suggesting that both vaccines confer 
protection against Covid-19 and complications from Covid-19 infection (10, 11). 
The potential risk conferred by the vaccines as judged by the safety profile which indicate mostly mild 
adverse events and a very low incidence of severe adverse events with no apparent marked differences 
between the vaccine and placebo groups. 
Vaccine efficacy for both vaccines was well above 90% in the pre-planned interim analysis (6, 7). 
However, it is not known to what extend the actually available immunogenicity, vaccine efficacy and 
safety data relate to immune compromised individuals. In both phase III trials of vaccines by Pfizer / 
BioNTech and Moderna no patients with organ transplants were included. In the trial by Pfizer / 
BioNTech and Moderna there were 121 and 179 HIV positive individuals included (6, 7). No subgroup 
data on trial efficacy and safety of these individuals and on the level of immunosuppression in this sub- 
population was reported. Also no data on immune response in HIV positive patients was reported. The 
present trial fills in this evidence gap by comparing the first two licensed vaccines in Switzerland against 
Sars-CoV-2 in immune compromised hosts. Nesting the trial into an existing cohort infrastructure allows 
for the monitoring of vaccine efficacy and long-term safety in an efficient and cost-saving way 
 
3.8 Justification of choice of study population 
According to the recommendation by the Bundesamt für Gesundheit (13) the following conditions define 
patient groups of high priority of vaccinations which include the primary target groups of this trial i.e. 
patients with HIV infection, solid organ transplantation and patients with these basic conditions plus 
additional comorbidities. The guidelines stress that due to the limited evidence on safety and efficacy of 
vaccines against SARS-CoV-2 patients with acquired immune deficiency and immune-suppressive 
therapy decision for vaccination has to be taken by the treating clinicians by considering risks and 
benefits for the individual patient. 
 
Comorbidity / Category organ system 
Priority Grouping 1: High risk BGP (Detailed 
definitions) 
Heart diseases 
- congestive heart failure NYHA II 
- Symptomatic chron. Ischemic coronary heart 
disease 
Hypertension 
- Hypertension with systolic blood pressure > 
160 mm HG regardless of antihypertensive 
therapy 
- Hypertension with cardiac complications and 
end organ damage 
Pulmonary diseases 
- COPD, stage GOLD II or above 
- Emphysema/severe bronchiectasis 
- Pneumopathy / Lung fibrosis 
- lung disease with severe reduction of vital 
capacity 
Kidney diseases 
- Severe chronic kidney disease with GFR 
<30ml/min/174m2 
Diabetes 
- Diabetes (Type 1 or 2) with relevant organ 
damage or HbA1c ≥8% 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 31 of 44 
 
 
Obesity 
- BMI ≥35 kg/m². 
Immunodeficiency*, 
inborne and acquired diseases and im- 
muno-suppressive therapy 
Relevant immunodeficiency with 
- malignant haematological disease 
- Neoplasia/cancer under active therapy 
- immune-mediated inflammatory diseases 
(e.g.. systemic lupus erythematodes, 
rheumatoid arthritis, psoriatic disease, 
chronic inflammatory bowel disease), with 
immunosuppressive therapy (including 
prednisolone-equivalent >20 mg/day, steroid- 
sparing therapy and biologicals). 
- HIV-Infection with CD4+ T cells < 200 / μL. 
- Organ transplantation, bone marrow or stem- 
cell transplantation, individuals on waiting list 
for transplantation 
 
4. STUDY OBJECTIVES 
 
4.1 Overall Objective 
We refer to the master protocol. 
 
4.2 Objectives related to platform trial set-up and feasibility of cohort based 
patient recruit, trial inclusion and data collection 
We refer to the master protocol. 
 
4.3 Objectives related to a platform based nested pilot trial to investigate the 
comparative effectiveness of vaccines against Sars-CoV-2 
The study seeks to determine the following SARS-CoV-2 related objectives (for detailed definitions see 
under 5 study endpoints) which are all developed according to FDA recommendations for phase III 
Covid-19 vaccine licensing trials (14)): 
• 
Immune response (pan-Ig antibodies against the receptor-binding domain (RBD) in the S1 
subunit of the spike protein (pan-Ig anti–S1-RBD) of SARS-CoV-2. 
• 
Newly PCR-confirmed asymptomatic SARS-CoV-2 infection, 
• 
Newly PCR-confirmed symptomatic SARS-CoV-2 infection 
• 
Severe COVID-19 infection, 
• 
COVID-19 burden of diseases (BOD) 
• 
Patient reported asymptomatic or symptomatic infections of household members. 
• 
Safety parameters 
o 
Adverse events from vaccines and 
o 
Serious adverse events 
 
4.4 Safety Objectives 
To evaluate the safety of vaccines in immunocompromised patients and risks for adverse events (AEs) 
and serious adverse events (SAEs). 
 
 
5. STUDY OUTCOMES 
 
For the feasibility outcomes we refer to the master protocol. 
 
 
5.1 Immunological Outcomes 
The primary immunological endpoint are antibodies to the SARS-CoV-2 spike (S1) protein receptor 
binding domain (RBD) in human serum and plasma assessed by the commercial immunoassay 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 32 of 44 
 
Elecsys® Anti-SARS-CoV-2 S for the in vitro quantitative determination (15). This assay detects pan- 
Ig antibody response (pan-Ig anti–S1-RBD) and allows for a quantitative assessment of the serological 
response of the participants at baseline and three months after vaccination. Additionally, we will 
qualitatively measure anti-Nucleocapsid (N) responses with Elecsys® Anti-SARS-CoV-2 N assay to 
gain a broader insight on the immune response of the participants. 
In addition SARS-CoV-2-binding antibody responses of the participants by analyzing the IgM, IgA and 
IgG responses to a wider range of SARS-CoV-2 proteins (S1, S2, RBD and N using an in-house method 
(ABCORA 2.0) established at the Institute of Medical Virology (IMV), UZH) will be measured. The 
ABCORA 2.0 test has an advantage over commercial available tests, as it allows a parallel assessment 
of IgG, IgM and IgA reactivity to multiple antigens enabling a high-dimensional temporal resolution of 
antibody responses and a dissection between humoral responses to an infection and vaccination 
 
5.2 Clinical Outcomes 
The clinical effectiveness endpoints are (according to FDA recommendations for phase III Covid-19 
vaccine licensing trials (14)) the following: 
- 
Newly PCR-confirmed asymptomatic COVID-19 infection (identified by the presence of anti– 
SARS-CoV-2 nucleocapsid antibodies or SARS-Cov-2 PCR or rapid antigen test) and no related 
symptoms [(i.e. fever or chills, cough, shortness of breath or difficulty breathing, fatigue, 
muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny 
nose nausea or vomiting, and diarrhea]) at any time point in within 48 weeks following 
randomisation. 
- 
Newly PCR-confirmed symptomatic COVID-19 infection with at least one of the following 
symptoms (i.e. fever or chills, cough, shortness of breath or difficulty breathing, fatigue, 
muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny 
nose, nausea or vomiting, and diarrhea at any time point in within 48 weeks following 
randomisation 
- 
severe COVID-19 infection with respiratory failure, evidence of shock (as diagnosed by a 
treating physician), clinically significant acute renal, hepatic, or neurologic dysfunction; 
admission to an intensive care unit; and death at any time point in within 48 weeks following 
randomisation. 
- 
COVID-19 burden of diseases (BOD), a composite of the above endpoints. The BOD is will be 
scored as by using 0 for no COVID-19, 1 for non-severe COVID-19, and 2 for severe COVID- 
19. 
 
An additional clinical effectiveness endpoint is patient reported asymptomatic or symptomatic 
infections of household members. 
 
All clinical outcomes will be measured in the trial database during a follow-up period of 48 weeks after 
randomisation and vaccination. 
 
 
5.3 Other Outcomes of Interest 
None. 
 
5.4 Safety Outcomes 
5.4.1 Collection of solicited local and systemic adverse events will for feasibility reasons be reduced 
to: 
• 
any local symptom (redness or swelling or prolonged pain at injection side) limiting 
continuation of normal daily activities during the first 7 days after vaccination 
• 
any systemic symptom (fever, generalized muscle or joint pain) limiting continuation of normal 
daily activities during the first 7 days after vaccination 
• 
any vaccine related symptom leading to contacting a physician during the first 7 days after 
vaccination 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 33 of 44 
 
6. STUDY DESIGN 
 
6.1 General study design and justification of design 
This is a pilot trial which is based on a trial platform that is integrated into the ongoing routine prospective 
data collection of two national cohorts, the SHCS and STCS. Eligibility of trial participants will be 
checked from routinely collected cohort data. Baseline data collection is done within cohorts. 
Randomisation and follow-up data collection of clinical trial endpoint data is done within the trial platform 
which is linked to the cohort database. The trial platform is overseen and managed by the two data 
centres of the SHCS and STCS. 
A parallel two-arm, open-label randomised controlled pilot trial comparing the first approved SARS-CoV- 
2 vaccines (Comirnaty® by Pfizer/ BioNTech and COVID-19 mRNA Vaccine Moderna® by Moderna) is 
planned to compare the immunogenicity, clinical effectiveness and safety of the first two licensed 
vaccines against Sars-CoV-2. 
Enrolment of patients is explained in figure 1 of the master protocol. Cohort data centres will identify 
eligible patients based on routinely collected cohort data and eligible patients will be flagged according 
to the priority vaccination criteria by the BAG and contacted for consent for participation prior to 
randomisation. Randomisation will be performed through minimisation with respect, center, age (<65, 
≥65 years old), sex, immune-suppression (<200 CD4 cells/μl in SHCS and uninterrupted prednisone 
treatment of at least 6 months in addition to standard immunosuppression in STCS) and a random 
element that reduces randomisation predictability. The minimisation will be conducted for each cohort 
separately. The trial platform allows to expand the pilot trial and to add further sub-study protocols to 
evaluate for example vaccine strategies in patients with a first vaccination but insufficient or lacking 
immune response (Figure 1 master protocol) 
 
6.2 Methods of minimising bias 
6.2.1 
Randomisation 
We refer to the master protocol. 
 
6.2.2 
Blinding procedures 
We refer to the master protocol. 
 
6.2.3 
Other methods of minimising bias 
We refer to the master protocol. 
 
6.3 Unblinding Procedures (Code break) 
Not applicable. 
 
 
7. STUDY POPULATION 
 
This is a multi-centre study recruiting patients from 4 of the 7 study centres of the SHCS and 3 of the 6 
study centres of the STCS (i.e. University Hospital Basel, University Hospital Zürich, and CHUV 
Lausanne). Both cohorts are representative for individuals living with HIV and solid organ transplants: 
 
SHCS study centres: 
• 
Department of Infectious Diseases, Bern University Hospital, University of Bern 
• 
Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel 
• 
Division of Infectious Diseases, University Hospital Lausanne, University of Lausanne 
• 
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University 
of Zurich 
 
 
 
STCS study centres: 
• 
Klinik für Pneumologie, Universitätsspital Zürich 
• 
Klinik für Nephrologie, Universitätsspital Zürich 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 34 of 44 
 
• 
CHUV Lausanne, Service des maladies infectieuses 
• 
CHUV Lausanne, Service de pneumologie 
• 
CHUV Lausanne Service de néphrologie 
• 
Universitätsspital Basel, Pneumologie 
• 
Universitätsspital Basel, Transplantationsimmunologie & Nephrologie, 
 
The cohorts are described in more detail elsewhere (8, 9, 16, 17). The study will be explained to eligible 
patients during their visit at the cohort centre. These visits will not be scheduled specifically for the 
purpose of this study. 
 
7.1 Eligibility criteria 
 
Inclusion and exclusion criteria as defined in the master protocol: 
Inclusion criteria: 
 
- All patients with either a chronic HIV infection or recipients of solid organs registered with informed 
consent from the SHCS and STCS cohorts aged ≥18 years 
- Patients with solid organ transplantation of lungs or kidneys at least one month post-transplantation 
with a prednisone dose of 20mg or less. 
- Additional consent for participation in the pilot trial 
- Covid-19 vaccination recommended by treating physician 
 
Exclusion criteria: 
- Pregnancy 
- Acute symptomatic SARS-CoV-2 infection, influenza or other acute respiratory tract infection 
- Known allergy or contra-indications for vaccines or any vaccine components 
- Any emergency condition requiring immediate hospitalization for any condition 
- Patients with previous PCR documented SARS-CoV-2 infection and, or documented antibodies less 
than 3 months prior to randomisation 
- Patients with solid organ transplantation (lung or kidney) with the following conditions: 
- Solid organ transplant recipients less than one month post-transplantation 
- Solid organ transplant recipients with the use of T-cell depleting agents in the last 3 months (i. e 
induction treatment in standard risk or high-risk immunological situation or rejection treatment). 
- Solid organ transplant recipients with the need of pulse corticosteroids (>100mg prednisone or 
equivalent) in the last 1 month or rituximab in the last 6 months 
- Solid organ transplant recipients with the need of any kind of chemotherapy treatment 
 
 
7.2 Recruitment and screening 
We refer to the master protocol. 
 
7.3 Assignment to study groups 
We refer to the master protocol. 
 
7.4 Criteria for withdrawal / discontinuation of participants 
We refer to the master protocol. 
 
 
8. STUDY INTERVENTION 
 
8.1 Identity of Investigational Products (treatment / medical device) 
(ICH/E6 6.2.1, 6.4.2, 6.4.4) 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 35 of 44 
 
ICH: A description of the trial treatment(s) and the dosage and dosage regimen of the investigational 
product(s). 
Describe all trial treatments for each arm of the study. 
 
 
8.1.1 
Experimental Intervention (treatment / medical device) 
ICH: Name and description of the investigational product(s). 
The COVID-19 mRNA Vaccine Moderna® is a white to off-white, sterile, preservative-free frozen 
suspension for intramuscular injection. The vaccine contains a synthetic messenger ribonucleic acid 
(mRNA) encoding the pre-fusion stabilized spike glycoprotein (S) of SARS-CoV-2 virus. The vaccine 
also 
contains 
the 
following  ingredients: 
lipids 
(SM-102, 
1,2-dimyristoyl-rac-glycero-3- 
methoxypolyethylene glycol-2000 [PEG2000-DMG], cholesterol, and 1,2-distearoyl-sn-glycero-3- 
phosphocholine [DSPC]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate, and 
sucrose. The COVID-19 mRNA Vaccine Moderna®(100 μg) is administer ed intramuscularly as a series 
of two doses (0.5 mL each), given 28 days apart. The vaccine is injected in the deltoid muscle. 
 
8.1.2 
Control Intervention (standard/routine/comparator treatment / medical device) 
ICH: Name and description of the investigational product(s). 
The COVID-19 Vaccine, BNT162b2 (30 µg) commercial name Comirnaty® developed by Pfizer / 
BioNTech, is administered intramuscularly (IM) as a series of two 30 µg doses of the diluted vaccine 
solution (0.3 mL each) according to the following schedule: a single dose followed by a second dose 28 
days later (12). BNT162b2 is supplied as a multiple-dose (5-dose) vial containing a frozen (between - 
80ºC to -60ºC suspension that is preservative-free. BNT162b2 must be thawed and diluted in its original 
vial with 1.8 mL of sterile 0.9% Sodium Chloride Injection, USP prior to administration. After dilution, the 
vial contains 5 doses of 0.3 mL per dose. After dilution, the multiple-dose vials must be stored between 
2°C to 25°C and used within 6 hours from the time of dilution.. 
 
8.1.3 
Packaging, Labelling and Supply (re-supply) 
ICH: Also include a description of the dosage form, packaging, and labelling of the investigational 
product(s). 
The COVID-19 mRNA Vaccine Moderna® is a suspension for Intramuscular Injection. 10 multiple- 
dose vials (each vial contains 10 doses of 0.5 mL). 5 ml dispersion in a vial (type 1 or type 1 equivalent 
glass) with a stopper (chlorobutyl rubber) and a flip-off plastic cap with seal (aluminium                  
seal). Each vial contains 10 doses of 0.5mL. Pack size: 10 multidose vials. Vials should be protected 
from light and be stored frozen between -25° to -15°C for a maximum of 30 days. The vaccine may not 
be stored on dry ice or temperature below -40°C. The vaccine should be prepared and administered  
by a trained healthcare professional using aseptic techniques to ensure sterility of the dispersion. The 
vaccine comes ready to use once thawed. One should not shake or dilute vials. Swirl the vial gently 
after thawing and before each withdrawal. COVID-19 mRNA Vaccine Moderna® vials are multidose. 
Ten (10) doses (of 0.5mL each) can be withdrawn from each vial. All details are provided in the 
reference    document    (https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine- 
moderna-epar-product-information_en.pdf). 
 
Comirnaty®(BNT162b2) is supplied as a multiple-dose (5-dose) vial containing a frozen (between -80ºC 
to -60ºC suspension that is preservative-free. BNT162b2 must be thawed and diluted in its original vial 
with 1.8 mL of sterile 0.9% Sodium Chloride Injection, USP prior to administration. After dilution, the vial 
contains 6 doses of 0.3 mL per dose. After dilution, the multiple-dose vials must be stored between 2°C 
to 25°C and used within 6 hours from the time of dilution. All details are provided in the reference 
document 
(https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-  
information_en.pdf). 
 
8.1.4 
Storage Conditions 
The COVID-19 mRNA Vaccine Moderna® is provided as a frozen suspension [stored between -25º to - 
15ºC] multi-dose vial containing 10 doses. The vaccine must be thawed prior to administration. After 
thawing, a maximum of 10 doses (0.5 mL each) can be withdrawn from each vial. Vials can be stored 
refrigerated between 2° to 8°C for up to 30 days prior to first use. Unopened vials may be stored between 
8° to 25°C for up to 12 hours. After the first dose has been withdrawn, the vial should be held between 
2° to 25°C and discarded after 6 hours. 
Storage, defreezing and preparation of vaccine doses will be done according to the fact sheets provided 
by 
Moderna 
(https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/storage-  
summary.pdf). 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 36 of 44 
 
Storage defreezing and preparation of vaccine doses will be done according to the fact sheets provided 
by Pfizer/ BioNTech (https://www.comirnatyeducation.ch/files/Checkliste_deutsch.pdf). 
 
8.2 Administration of experimental and control interventions 
8.2.1 
Experimental Intervention 
ICH: Description of and justification of the treatment(s) to be administered, including the name(s) of all 
the product(s), the dose(s), the dosing schedule(s), the route/mode(s) of administration, and the 
treatment period(s), including the follow-up period(s) for subjects for each investigational product 
treatment/trial treatment group/arm of the trial. 
The COVID-19 mRNA Vaccine Moderna® (100 μg) is administered intramuscularly as a series of two 
doses (0.5 mL each), given 28 days  apart  (12). The  vaccine  is  injected  in  the  deltoid muscle  
https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/prep-and-admin-  
summary.pdf. 
Preparation of vaccines (defreezing, dilution of ampules) and syringes for vaccination are done strictly 
according to the specifications of the producer and the guidelines by the BAG and eidgenössische 
Kommission 
für 
Impffragen 
(EKIF) 
https://www.bag.admin.ch/dam/bag/de/dokumente/mt/k-und-  
i/aktuelle-ausbrueche-pandemien/2019-nCoV/impfempfehlung-covid-19.pdf.download.pdf/Covid-19-  
Impfempfehlung%20f%C3%BCr%20mRNA-Impfstoffe_120121.pdf. 
 
 
8.2.2 
Control Intervention 
ICH: Description of and justification of the treatment(s) to be administered, including the name(s) of all 
the product(s), the dose(s), the dosing schedule(s), the route/mode(s) of administration, and the 
treatment period(s), including the follow-up period(s) for subjects for each investigational product 
treatment/trial treatment group/arm of the trial. 
The Pfizer / BioNTech COVID-19 Vaccine, BNT162b2 (30 µg), is administered intramuscularly (IM) 
as a series of two 30 µg doses of the diluted vaccine solution (0.3 mL each) according to the following 
schedule: a single dose followed by a second dose 28 days later (12). 
BNT162b2 is supplied as a multiple-dose (5-dose) vial containing a frozen (between -80ºC to -60ºC 
suspension that is preservative-free. BNT162b2 must be thawed and diluted in its original vial with 1.8 
mL of sterile 0.9% Sodium Chloride Injection, USP prior to administration. After dilution, the vial contains 
6 doses of 0.3 mL per dose. After dilution, the multiple-dose vials must be stored between 2°C to 25°C 
and used within 6 hours from the time of dilution. Details for storage and preparation are provided in the 
checkliste by Pfizer / BioNTech (Checkliste für die Lagerung, Handhabung und Zubereitung des 
COMIRNATY® 
COVID-19 
mRNA-Impfstoffs  
https://www.comirnatyeducation.ch/files/Checkliste_deutsch.pdf. 
Preparation of vaccines (defreezing, dilution of ampules) and syringes for vaccination are done strictly 
according to the specifications of the producer and the guidelines by the BAG and eidgenössische 
Kommission 
für 
Impffragen 
(EKIF). 
https://www.bag.admin.ch/dam/bag/de/dokumente/mt/k-und-  
i/aktuelle-ausbrueche-pandemien/2019-nCoV/impfempfehlung-covid-19.pdf.download.pdf/Covid-19-  
Impfempfehlung%20f%C3%BCr%20mRNA-Impfstoffe_120121.pdf 
 
8.3 Dose / Device modifications 
(SPIRIT #11b) 
Trial participants are vaccinated according to the producers’ dosing recommendations. No adaptation 
of vaccine dosing is planned. In case of a serious adverse event following the application of a first dose, 
the second dose will not be given. 
 
 
8.4 Compliance with study intervention 
The application of the one-time injection by the treating physician (or a delegated person) will be 
documented in the trial platform data entry form and the batch number of the vaccine will be entered. 
 
 
8.5 Data Collection and Follow-up for withdrawn participants 
Patients have the right to withdraw the planned follow-up visits. Clinical outcomes for those patients will 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 37 of 44 
 
be assessed from routinely collected cohort data. 
 
8.6 Trial specific preventive measures 
(ICH/E6 6.6.2; SPIRIT #11d) 
ICH: Medication(s)/treatment(s) permitted (including rescue medication) and not permitted before and/or 
during the trial. 
All patients included into the trial will continue all medication taken for the treatment of their chronic 
conditions. No drugs are prohibited that would exempt participation from the trial except use of ATG or 
rituximab within 6 months and pulse corticosteroids within 1 months prior to first vaccination for solid 
organ transplant patients. For transplanted patients with recent organ transplant receipt and / or more 
severe immune-suppressant treatment, decision to vaccinate patients and for trial participation is taken 
by the treating physicians by considering all benefit and potential harms for vaccination against Sars- 
CoV-2 in a particular patient. 
Use of any drugs for the treatment of local or systemic adverse effects of vaccines is according to clinical 
judgement by clinicians. 
 
8.7 Concomitant Interventions (treatments) 
ICH/E6 6.6.2; SPIRIT #11d) 
ICH: Medication(s)/treatment(s) permitted (including rescue medication) and not permitted before and/or 
during the trial. 
All concomitant drugs for patients included into the trial are recorded within the routine cohort based 
data collection structure (see master protocol). Physicians are free in the choice of any concomitant 
drugs for the treatment of HIV, immunosuppressants for transplanted patients or any other drugs used 
for the treatment of additional chronic conditions and take decisions for their use according to best 
clinical judgement and treatment guidelines. There are no particular drugs that are not permitted for their 
use during vaccination and follow-up. 
 
Use of any drugs for the treatment of local or systemic adverse effects of vaccines is according to clinical 
judgement by clinicians. 
 
 
8.8 Study Drug / Medical Device Accountability 
(ICH/E6 6.4.7; SPIRIT 11c) 
ICH: Accountability procedures for the investigational product(s), including the placebo(s) and 
comparator(s), if any. 
Vaccines will be shipped to the pharmacies of the four participating university hospital in cooled 
containers guaranteeing temperatures during transport of -60 degrees C based on recommendations 
by the vaccine producers and the Bundesamt für Gesundheit. Vaccines will be shipped by cantonal 
vaccine storage facilities directly to hospitals for same day use or stored in refrigerators by university 
hospital pharmacies at the requested temperatures, defrozen and deluted according to prescribed rules 
of producers and prepared in sterile syringes for vaccination in batches of 6 and 5 vaccinations for the 
Pfizer / BioNTech and for the Moderna vaccine. 
 
 
8.9 Return or Destruction of Study Drug / Medical Device 
Does not apply. Since the vaccines will be a product which has received marked authorisation in 
Switzerland, unused vaccines will immediately be used for other patients vaccinated at the respective 
clinical sites based on the clinical judgement of physicians and according to the priority rules set by the 
BAG. 
 
 
9. STUDY ASSESSMENTS 
 
9.1 Study flow chart(s) / table of study procedures and assessments 
Figure 1: Study flow chart. 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 38 of 44 
 
 
 
 
 
9.2 Assessments of outcomes 
9.2.1 
Assessment of feasibility outcomes 
We refer to the master protocol. 
 
9.2.2 
Assessment of immunological endpoints 
We will assess pan-IgG anti S (RBD) (quantitative) and anti- N antibodies (qualitative) with the 
commercial Elecsys® Anti-SARS-CoV-2 tests at baseline and at 12 weeks following randomisation and 
vaccination (primary immunological endpoint). 
We will assess SARS-CoV-2-binding antibody responses of the participants by analyzing the IgM, IgA 
and IgG responses to a wider range of SARS-CoV-2 proteins (S1, S2, RBD and N using an in-house 
method (ABCORA2.0) established at the Institute of Medical Virology (IMV), UZH (secondary 
immunological endpoint). The ABCORA 2.0 test allows for a parallel assessment of IgG, IgM and IgA 
reactivity to multiple antigens enabling a high-dimensional temporal resolution of antibody responses 
and a dissection between humoral responses to an infection and vaccination. We expect that the 
ABCORA2.0 antibody test will be more sensitive than the Elecsys® Anti-SARS-CoV-2 S antibody test. 
 
Patients will be invited to see their treating physician 12 weeks after randomisation (see Study schedule). 
During baseline and follow-up visits this visit a blood sample will be taken (EDTA blood (2 x 7.5 ml)) 
and assessed for the above listed antibodies: 
• 
1ml for Elecsys® Anti-SARS-CoV-2 N and S tests (performed locally at each laboratory) 
• 
2ml EDTA Plasma for ABCORA 2.0 test (performed at IMV, UZH) 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 39 of 44 
 
EDTA blood should be processed within 24h and EDTA plasma should be stored at -20°C. For ABCORA 
2.1 antibody measurements plasma samples will be collected at each center and a collective shipment 
will be sent after baseline and at 12 weeks after randomisation and vaccination to the IMV, UZH. One 
sample will be stored according to SHCS and STCS protocols for later eventual analyses at the centers 
of University Hospital Zurich. 
 
9.2.3 
Assessment of clinical endpoints 
Patients are informed to contact center physicians in case an asymptomatic or symptomatic SARS-Cov- 
2 infections was diagnosed outside the settings of participating cohort centers. Clinical endpoints will be 
assessed at 12 and 48 weeks, and during each cohort visits, that fall in between the trial specific visit 
dates. 
• 
Newly PCR-confirmed asymptomatic Covid-19 infection (identified by the presence of anti– 
SARS-CoV-2 nucleocapsid antibodies ,or PCR or rapid antigen test) and no related symptoms 
[(i.e. fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body 
aches, headache, new loss of taste or smell, sore throat, congestion or runny nose nausea or 
vomiting, and diarrhea]) at any time during the 48 weeks of follow-up 
During all visits at the trial centres (study specific at 12 and 48 weeks, as well as cohort visits) a PCR 
SARS-COV-2 test will only be conducted if the treating physician would also conduct such a test during 
clinical routine (e.g. exposure to infected individual). PCR tests done in between independently will be 
recorded with dates and results. In case of a positive test result, physicians will check for symptoms 
and patients will be followed-up according to clinical routine and physicians’ judgement. 
 
• 
Newly PCR-confirmed symptomatic Covid-19 infection with at least one of the following 
symptoms (i.e. fever or chills, cough, shortness of breath or difficulty breathing, fatigue, 
muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny 
nose nausea or vomiting, and diarrhea) at any time during the 48 weeks of follow-up 
During all visits at the trial centres (study specific at 12 and 48 weeks, as well as cohort visits) a PCR 
SARS-COV-2 test will only be conducted if the treating physician would also conduct such a test during 
clinical routine (e.g. COVID-19 related symptoms; exposure to infected individual). In case of a positive 
test result, physicians will check for symptoms and patients will be followed-up according to clinical 
routine and physicians’ judgement. 
 
 
• 
Severe COVID-19 infection with respiratory failure, evidence of shock (as diagnosed by a 
treating physician), clinically significant acute renal, hepatic, or neurologic dysfunction; 
admission to an intensive care unit; or death at any time during the 48 weeks of follow-up. 
 
 
• 
COVID-19 burden of diseases (BOD), a composite of the above endpoints. The BID is will be 
scored as by using 0 for no COVID-19, 1 for non-severe COVID-19, and 2 for severe COVID- 
19. 
 
The burden of diseases endpoint will be assessed by combining the before listed outcomes (i.e. no 
COVID-infection, non-severe COVID-19 infection 
 
• 
Patient reported asymptomatic or symptomatic infections of household members. 
Patients will be asked at the 12-week and 48-week visit if a household member was diagnosed with 
COVID-19. 
 
9.2.4 
Assessment of safety outcomes 
 
9.2.4.1 
Adverse events following vaccination 
 
Any local symptom (redness or swelling or prolonged pain at injection side) continuation of 
normal daily activities during the first 7 days after vaccination 
During the 12-week visit, patients will be asked if they had any local symptoms which limited 
their daily activities during the first 7 days after vaccination. 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 40 of 44 
 
• 
Any systemic symptom (fever, generalized muscle or joint pain) limiting continuation of 
normal daily activities during the first 7 days after vaccination. 
 
During the 12-week visit, patients will be asked if they had any systemic symptoms after 
randomisation which limited their daily activities during the first 7 days after vaccination. 
 
• 
Any vaccine related symptom leading to contacting a physician during the first 7 days after 
vaccination 
During the 12-week visit, patients will be asked if they had to contact a physician within 7 days 
after vaccination. 
 
9.2.4.2 
Serious adverse events 
For reporting of serious adverse events we will adhere to the ICH E2A guidelines (18) and define a 
serious adverse event (experience) or reaction ‘as any untoward medical occurrence that at any dose 
results in death, is life-threatening, requires inpatient hospitalisation or prolongation of existing 
hospitalisation, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth 
defect. Exemptions will be SARS-CoV-2 related deaths or SARS-CoV-2 related hospitalisations, which 
are among the assessed clinical outcomes. The term "life-threatening" in the definition of "serious" refers 
to an event in which the patient was at risk of death at the time of the event; it does not refer to an event 
which hypothetically might have caused death if it were more severe’. 
 
9.2.4.3 
Laboratory parameters 
Laboratory parameters besides immune response parameters will be assessed at bi-annually cohort 
visits according to the cohort protocols. 
 
9.2.4.4 
Vital signs 
Not relevant for purpose of this trial. 
 
9.2.5 
Assessments in participants who prematurely stop the study 
All clinical outcomes will be assessed from routinely collected cohort data which will also be available if 
patients decide to prematurely stop participating in the clinical trial. 
 
9.2.6 
Assessments in participants who prematurely stop the study 
We refer to the master protocol 
 
9.3 Procedures at each visit 
9.3.1 
Eligibility (and eventual enrolment, randomisation) 
We refer to the master protocol. 
 
9.3.2 
Enrolment and randomisation 
We refer to the master protocol. 
 
9.3.3 
Follow-up 1 week 12 
We refer to the master protocol. 
 
9.3.4 
Follow-up 2 week 48 
We refer to the master protocol. 
 
 
10. SAFETY 
 
10.1 Drug studies 
10.1.1 Reporting of serious adverse events (SAE) and other safety related events 
We refer to the master protocol. 
In addition to reporting of all SAE to the sponsor / principle investigators according to the rules set by 
Swissmedic all study physicians must report SAE via the ElViS (Elektronisches Vigilance-Meldesystem) 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 41 of 44 
 
to Swissmedic (https://www.swissmedic.ch/swissme-dic/de/home/services/egov-services/elvis.html). 
All study physicians must register at ElViS. 
 
10.1.2 Follow up of (Serious) Adverse Events 
We refer to the master protocol. 
 
 
11. STATISTICAL METHODS 
 
11.1 Hypothesis 
To compare the effectiveness in term of serological immune response of approved SARS-CoV-2 
vaccines in immunocompromised patients, we aim to demonstrate that the second vaccine available in 
the market is no worse than the comparator by more than 10%. Therefore, we formulate the null 
hypothesis H0: π1 ≥ π2 + 10 versus the alternative hypothesis H1: π1 -10 < π2. The choice of a non- 
inferiority margin of 10% relies on expert opinion/clinical judgment. 
 
11.2 Determination of Sample Size 
Phase 1 to Phase 3 trials of COVID-19 mRNA Vaccine Moderna® and Comirnaty® (Pfizer / BioNTech) 
report immunological response titers that are not comparable due to the different assays that were used. 
Moderna uses an in-house developed ELISA assay,  while Pfizer / BioNTech uses an in-house 
developed Luminex assay. However, currently available results show that titers are high at 4 weeks post 
vaccination and the proportion of patients that is reactive to vaccination is close to 100 percent (19, 20). 
However, no data is available for an immunocompromised population such as the one in our study. By 
assuming vaccine reactivity of 90% in both vaccine groups, we power our non-inferiority trial such that 
a 95% two-sided confidence interval excludes a difference in favour of the reference group of more than 
10%. A sample size of 380 (190 in each treatment arm) is required for a statistical power of 90% and a 
type I error of 0.025. We believe that a target sample of 380 patients participants is feasible, which 
represents 32 patients distributed across 6 participating centres. Sample size was calculated using the 
“ssc_propcomp” function of the R statistical software package “SampleSize4ClinicalTrials’ (21). 
 
11.3 Statistical criteria of termination of trial 
Not applicable. No interim analysis is planned during the pilot trial and termination will not be based on 
any statistical criteria. 
 
11.4 Planned Analyses 
11.4.1 Datasets to be analysed, analysis populations 
We refer to the master protocol 
 
11.4.2 Feasibility analysis 
We refer to the master protocol. 
 
11.4.3 Analyses of immunological and clinical outcomes 
Immunological outcomes at baseline and 12-week follow-up will be reported as frequency and 
percentage of positive serologic immune response for both vaccine arms. The primary objective is to 
assess the non-inferiority of the second licensed vaccine versus the first licensed vaccine in regards to 
the presence of pan-IgG antibody, as measured by the Elecsys® Anti-SARS-CoV-2 S immunoassay. 
Difference in primary outcome among the two vaccine arms will be assessed by a two-sided 95% 
confidence interval, showing a credible range for the true difference between the second licensed 
vaccine and the first licensed vaccine. Non-inferiority will be established at the α significance level, if the 
lower limit of a 95% two-sided Wald confidence interval for the difference (second licensed– first 
licensed) is above –10%, where 10% is the pre-defined non-inferiority margin. 
We will report frequency and percentage of positive serological immune response for both vaccine arms 
among different pre-specified subgroups of patients most prone to complicated infections with SARS- 
CoV-2. These are for HIV positive individuals, patients with less than 200 CD4cell/µL, unsuppressed HI 
viral load, male gender, age group 60 to 69, 70 older and history of cardiovascular diseases or present 
metabolic syndrome. For transplanted individuals these are patients with less than 200 CD4cell/µL, 
intense versus less intense immunosuppressive therapy, male gender, age group 60 to 69, 70 older and 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 42 of 44 
 
history of cardiovascular diseases or present metabolic syndrome. 
A secondary and tertiary analysis will assess the non-inferiority of the second licensed vaccine versus 
the first licensed vaccine in regards to the presence of anti-Nucleocapsid (N), as measured by the 
Elecsys® Anti-SARS-CoV-2 N assay and the presence of IgM, IgA and IgG as measured by the 
ABCORA 2.0 assay. 
Clinical outcomes related to COVID-19 infection at 48 weeks and patient reported COVID-19 infection 
of household members will be reported as frequency with percentage for the different treatment arms. 
 
11.4.4 Interim analyses 
No interim analysis will be done 
 
11.4.5 Safety analysis 
Results from a phase 3 randomised, observer-blinded, placebo-controlled trial conducted at 99 centers 
across US on 30,420 volunteers reported that no safety concerns were identified, aside from transient 
local and systemic reactions for the COVID-19 mRNA Vaccine Moderna®. For BNT16b2 vaccine 
Comirnaty® (Pfizer / BioNTech), a randomised placebo-controlled trial on 43,548 participants showed 
short-term, mild-to-moderate pain at the injection site, fatigue and headache. The incidence of serious 
adverse events was low and similar in the vaccine and placebo groups (6). Therefore, we expect safety 
issue to be small and do not believe that we will have enough power to demonstrate any statistical 
difference between the treatment arms. 
 
11.4.6 Deviation(s) from the original statistical plan 
We refer to the master protocol 
 
11.5 Handling of missing data and drop-outs 
We refer to the master protocol. 
 
 
12. QUALITY ASSURANCE AND CONTROL 
 
12.1 Data handling and record keeping / archiving 
We refer to the master protocol. 
 
12.2 Data management 
We refer to the master protocol. 
 
12.3 Monitoring 
We refer to the master protocol. 
 
12.4 Audits and Inspections 
We refer to the master protocol. 
 
12.5 Confidentiality, Data Protection 
We refer to the master protocol. 
 
12.6 Storage of biological material and related health data 
Samples used for diagnostic will be stored for 5 years. 
Samples for the ABCORA2.0 and Elecsys® Anti-SARS-CoV-2 S and N tests will be locally stored at the 
University Hospital virology laboratories and will be shipped by two shipments for all samples collected 
at baseline after completion of recruitment and after completion of the 3 months follow-up in all patient 
for all samples collected at three-month follow-up. Samples will be sent to the Institute of Medical 
Virology, University of Zurich and will be evaluated centrally. 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 43 of 44 
 
13. PUBLICATION AND DISSEMINATION POLICY 
 
We refer to the master protocol. 
 
 
14. FUNDING AND SUPPORT 
 
We refer to the master protocol. 
 
 
15. INSURANCE 
 
We refer to the master protocol. 
 
 
16. REFERENCES 
 
1. 
WHO: Pneumonia of unknown cause – China. WHO. https://www.who.int/csr/don/05-january-  
2020-pneumonia-of-unkown-cause-china/en/ [accessed: 8 December 2020]. 
2. 
Zhu RF, Gao YL, Robert SH, Gao JP, Yang SG, Zhu CT. Systematic review of the registered 
clinical trials for coronavirus disease 2019 (COVID-19). J Transl Med. 2020;18(1):274. 
3. 
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health 
concern. Lancet. 2020;395(10223):470-3. 
4. 
Swissmedic.  Swissmedic  erteilt  die  Zulassung  für  den  Covid-19  Impfstoff  von  Moderna.  
https://www.swissmedic.ch/swissmedic/de/home/news/coronavirus-covid-19/zulassung-covid-19-  
impfstoff-moderna.html [accessed: 26 January 2021]. 
5. 
Swissmedic. Swissmedic erteilt Zulassung für den ersten Covid-19-Impfstoff in der Schweiz.  
https://www.swissmedic.ch/swissmedic/de/home/news/coronavirus-covid-19/covid-19-  
impfstoff_erstzulassung.html [accessed: 26 January 2021]. 
6. 
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy 
of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15. 
7. 
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA 
Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020;383(20):1920-31. 
8. 
Swiss Transplant Cohort Study (STCS). https://www.stcs.ch/about/study-description [accessed: 
8 December 2020]. 
9. 
Swiss HIV Cohrot Study (SHCS). http://www.shcs.ch/ [accessed: 8 december 2020]. 
10. 
PFIZER-BIONTECH COVID-19 VACCINE (BNT162, PF-07302048). VACCINES AND 
RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE BRIEFING DOCUMENT MEETING 
DATE: 10 December 2020. https://www.fda.gov/media/144246/download [accessed: 26 January 2021]. 
11. 
FDA Briefing Document: Moderna COVID-19 Vaccine. Vaccines and Related Biological 
Products 
Advisory 
Committee 
Meeting 
December 
17, 
2020.  
https://www.fda.gov/media/144434/download [accessed: 26 January 2021]. 
12. 
Bundesamt für Gesundheit (BAG) und Eidgenössische Kommission für Impffragen (EKIF). 
Impfempfehlung 
für 
mRNA-Impfstoffe 
gegen 
Covid-19 
(Stand 
12.01.21).  
https://www.bag.admin.ch/dam/bag/de/dokumente/mt/k-und-i/aktuelle-ausbrueche-pandemien/2019-  
nCoV/impfempfehlung-covid-19.pdf.download.pdf/Covid-19-  
Impfempfehlung%20f%C3%BCr%20mRNA-Impfstoffe_120121.pdf [accessed: 1 February 2021]. 
13. 
Federal 
Office 
of 
Public 
Health. 
Coronavirus: 
Vaccination.  
https://www.bag.admin.ch/bag/en/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-  
ausbrueche-epidemien/novel-cov/impfen.html#-739379966 [accessed: 26 January 2021]. 
14. 
Food and Drug Administration. Development and Licensure of Vaccines to Prevent COVID-19. 
Guidance 
for 
Industry. 
https://www.fda.gov/regulatory-information/search-fda-guidance-  
documents/development-and-licensure-vaccines-prevent-covid-19 [accessed: 8 December 2020]. 
15. 
Roche. Elecsys®Covid-19 Solutions. https://go.roche.de/diagnostics/tests-parameter/elecsys-  
anti-sars-cov-2.html#Elecsys-Anti-SARS-CoV-2-S [accessed: 14 December 2020]. 

COVERALL, sub-protocol 1, Version 1.1 (07/04/2021) 
Page 44 of 44 
 
16. 
Koller MT, van Delden C, Muller NJ, Baumann P, Lovis C, Marti HP, et al. Design and 
methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide 
long-term follow-up cohort. Eur J Epidemiol. 2013;28(4):347-55. 
17. 
Swiss HIVCS, Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Gunthard HF, et al. 
Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol. 2010;39(5):1179-89. 
18. 
European Medicines Agency. ICH E2A Clinical safety data management: definitions and 
standards 
for 
expedited 
reporting. 
https://www.ema.europa.eu/en/ich-e2a-clinical-safety-data-  
management-definitions-standards-expedited-reporting [accessed: 8 December 2020]. 
19. 
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of 
COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589-93. 
20. 
Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al. Durability 
of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med. 2021;384(1):80-2. 
21. 
Chow S, Shao J, Wang H. 2008. Sample Size Calculations in Clinical Research. 2nd Ed. 
Chapman & Hall/CRC Biostatistics Series. 
 
 
 
17. APPENDICES 
 
Not applicable